Adaptimmune Therapeutics (ADAP) Shares Up 0.8%

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) shot up 0.8% on Thursday . The company traded as high as $11.74 and last traded at $11.49. 507,722 shares traded hands during trading, a decline of 17% from the average session volume of 612,463 shares. The stock had previously closed at $11.40.

A number of research firms recently weighed in on ADAP. BidaskClub raised shares of Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Friday. Leerink Swann reaffirmed an “outperform” rating on shares of Adaptimmune Therapeutics in a report on Thursday, March 15th. Zacks Investment Research lowered shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, March 19th. Finally, ValuEngine lowered shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $11.58.

How to Become a New Pot Stock Millionaire

The stock has a market capitalization of $1,068.03, a price-to-earnings ratio of -13.86 and a beta of 1.79.

In related news, major shareholder Enterprise Associates 14 New acquired 1,268,508 shares of Adaptimmune Therapeutics stock in a transaction on Friday, March 23rd. The shares were purchased at an average cost of $1.91 per share, for a total transaction of $2,422,850.28. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Ravi Viswanathan acquired 104,844 shares of Adaptimmune Therapeutics stock in a transaction on Wednesday, March 21st. The shares were bought at an average price of $1.81 per share, for a total transaction of $189,767.64. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 2,242,926 shares of company stock valued at $4,264,809. Company insiders own 24.45% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Raymond James & Associates bought a new position in Adaptimmune Therapeutics during the 4th quarter valued at $114,000. Cubist Systematic Strategies LLC bought a new position in Adaptimmune Therapeutics during the 3rd quarter valued at $182,000. Dynamic Technology Lab Private Ltd bought a new position in Adaptimmune Therapeutics during the 3rd quarter valued at $199,000. Iguana Healthcare Management LLC bought a new position in Adaptimmune Therapeutics during the 3rd quarter valued at $205,000. Finally, Arrowstreet Capital Limited Partnership bought a new position in Adaptimmune Therapeutics during the 4th quarter valued at $244,000. Hedge funds and other institutional investors own 55.58% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3294882/adaptimmune-therapeutics-adap-shares-up-0-8.html.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Zacks: Analysts Expect Bank Of Princeton  to Post $0.51 EPS
Zacks: Analysts Expect Bank Of Princeton to Post $0.51 EPS
Energen  Earns Buy Rating from Stephens
Energen Earns Buy Rating from Stephens
Smart Sand  Expected to Post Earnings of $0.08 Per Share
Smart Sand Expected to Post Earnings of $0.08 Per Share
JetPay  Getting Favorable News Coverage, Accern Reports
JetPay Getting Favorable News Coverage, Accern Reports
Glen Burnie Bancorp  Receives News Sentiment Rating of -0.08
Glen Burnie Bancorp Receives News Sentiment Rating of -0.08
MKS Instruments  Releases Q2 Earnings Guidance
MKS Instruments Releases Q2 Earnings Guidance


© 2006-2018 Ticker Report. Google+.